Asier Unciti-Broceta Research Group

Innovative Therapeutics

Professor Asier Unciti-Broceta

Personal Chair of Medicinal Chemistry

Contact details

Research in a Nutshell

The Innovative Therapeutics Lab is led by Professor Asier Unciti-Broceta and based at Edinburgh Cancer Research, part of the Institute of Genetics and Cancer at the University of Edinburgh, where Asier established the first chemistry lab of the Institute in 2010. The lab explores novel chemical strategies to improve the efficacy and safety of cancer treatments. This includes development of highly-selective inhibitors of kinases involved in cancer and novel prodrug strategies aimed at improving the clinical use of well-established chemotherapy drugs.

Asier Unciti-Broceta Research Group

People

NameRole
Asier Unciti-BrocetaProfessor of Medicinal Chemistry and Head of the Innovative Therapeutics Lab
Catherine AdamChemistry Lab Manager
Alvaro Lorente-MacíasLead Synthetic Chemist
Yang GeEPSRC Postdoctoral Fellow
Athina PolykandritouMRC Postdoctoral Fellow
Davir GonzálezEPSRC Postdoctoral Fellow
Bobby KaghazchiNuvectis Postdoctoral Fellow
Ben KingPhD student
Iñigo Lanzagorta CalvilloPhD student
Jonathon MockPhD student
Ross MilnesPhD student
Adam SmithPhD student
Ben JonesVisiting PhD student
John Hajek5th year MChem student

Key Publications

Collaborations

  • Professor Neil Carragher (ECRC)
  • Dr Liz Patton (ECRC)
  • Professor Val Brunton (ECRC)
  • Professor Margaret Frame (ECRC)
  • Professor H. Leung (Beatson Institute / University of Glasgow)
  • Dr P. Brennan (Centre for Clinical Brain Sciences / University of Edinburgh)
  • Dr D. Sieger (Centre for Neuroregeneration / University of Edinburgh)
  • Dr C. Torres-Sánchez (Loughborough University)
  • Dr R. Sanchez-Martín and Dr J. J. Díaz-Mochón (GENyO / Spain)
  • Professor I. Molina (University of Granada / Spain)

 

Scientific Themes

Anticancer Therapy, Kinase Inhibitors, Bioorthogonal Prodrugs, Palladium Implants, Nanotechnology

Technology Expertise

Small Molecule Synthesis and Peptides, Medicinal Chemistry, Design and Development of Prodrugs, Target ID and Imaging Tools, Heterogeneous Catalysts

This article was published on